MUFG Americas Holdings Corp Trims Holdings in GlaxoSmithKline plc (GSK)

MUFG Americas Holdings Corp reduced its stake in GlaxoSmithKline plc (NYSE:GSK) by 47.1% during the fourth quarter, Holdings Channel reports. The fund owned 27,344 shares of the pharmaceutical company’s stock after selling 24,300 shares during the quarter. MUFG Americas Holdings Corp’s holdings in GlaxoSmithKline were worth $970,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Fisher Asset Management LLC increased its holdings in GlaxoSmithKline by 2.3% in the 3rd quarter. Fisher Asset Management LLC now owns 12,828,251 shares of the pharmaceutical company’s stock valued at $520,827,000 after acquiring an additional 293,866 shares during the last quarter. Hotchkis & Wiley Capital Management LLC increased its holdings in GlaxoSmithKline by 7.3% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 8,416,927 shares of the pharmaceutical company’s stock valued at $341,727,000 after acquiring an additional 569,600 shares during the last quarter. NWQ Investment Management Company LLC increased its holdings in GlaxoSmithKline by 9.4% in the 3rd quarter. NWQ Investment Management Company LLC now owns 2,728,458 shares of the pharmaceutical company’s stock valued at $110,775,000 after acquiring an additional 233,689 shares during the last quarter. Ameriprise Financial Inc. increased its holdings in GlaxoSmithKline by 7.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 1,855,142 shares of the pharmaceutical company’s stock valued at $75,028,000 after acquiring an additional 122,634 shares during the last quarter. Finally, Hamlin Capital Management LLC increased its holdings in GlaxoSmithKline by 0.4% in the 3rd quarter. Hamlin Capital Management LLC now owns 1,772,997 shares of the pharmaceutical company’s stock valued at $71,984,000 after acquiring an additional 7,882 shares during the last quarter. Institutional investors own 9.52% of the company’s stock.

Shares of GlaxoSmithKline plc (NYSE:GSK) opened at $37.70 on Friday. GlaxoSmithKline plc has a fifty-two week low of $34.52 and a fifty-two week high of $44.53. The company has a quick ratio of 0.39, a current ratio of 0.60 and a debt-to-equity ratio of 4.09. The firm has a market cap of $93,461.99, a PE ratio of 13.04, a PEG ratio of 2.37 and a beta of 0.98.

GlaxoSmithKline (NYSE:GSK) last posted its earnings results on Wednesday, February 7th. The pharmaceutical company reported $0.72 earnings per share for the quarter, topping analysts’ consensus estimates of $0.69 by $0.03. GlaxoSmithKline had a net margin of 4.97% and a return on equity of 130.63%. The firm had revenue of $10.14 billion for the quarter, compared to the consensus estimate of $9.89 billion. research analysts anticipate that GlaxoSmithKline plc will post 2.85 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, April 12th. Stockholders of record on Friday, February 23rd will be issued a $0.633 dividend. The ex-dividend date is Thursday, February 22nd. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.50. This represents a $2.53 dividend on an annualized basis and a dividend yield of 6.72%. GlaxoSmithKline’s payout ratio is 258.23%.

GSK has been the topic of a number of research reports. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of GlaxoSmithKline in a report on Tuesday, October 24th. Zacks Investment Research downgraded shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Tuesday, October 24th. Bank of America downgraded shares of GlaxoSmithKline from a “buy” rating to a “neutral” rating in a report on Thursday, October 26th. TheStreet upgraded shares of GlaxoSmithKline from a “c+” rating to a “b” rating in a report on Wednesday, October 25th. Finally, Investec downgraded shares of GlaxoSmithKline from a “buy” rating to a “hold” rating in a report on Monday, November 6th. Two analysts have rated the stock with a sell rating, ten have issued a hold rating and six have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $38.97.

WARNING: “MUFG Americas Holdings Corp Trims Holdings in GlaxoSmithKline plc (GSK)” was originally reported by Week Herald and is the property of of Week Herald. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://weekherald.com/2018/02/18/mufg-americas-holdings-corp-trims-holdings-in-glaxosmithkline-plc-gsk.html.

About GlaxoSmithKline

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline plc (NYSE:GSK).

Institutional Ownership by Quarter for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply